2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 778

Relationship of Meeting Physical Activity Guidelines and Quality Adjusted Life Years
Abstract Number: 2753

Relationship Of Pre-Radiographic MRI Lesions With Prevalent Frequent Knee Symptoms and Incident Persistent Knee Symptoms In Persons At Higher Risk For Knee Osteoarthritis
Abstract Number: 831

Relationships Between Clinical Outcome Measures and Gait Variables Before and After Total Hip Arthroplasty
Abstract Number: 1760

Relationships Between Driving Distance, Rheumatoid Arthritis Diagnosis, and Disease-Modifying Anti-Rheumatic Drug Receipt
Abstract Number: 2176

Relationships Between Physician and Patient Scored Clinical Outcome Measures In Pediatric Localized Scleroderma
Abstract Number: 2103

Relationships Between Self-Efficacy, Outcome Expectancy, and Outcomes In Older Adults With Osteoarthritis Of The Knee and Hypertension: Baseline Results
Abstract Number: 2788

Reliability and Responsivenss Of The Standardized Universal Pain Evaluations For Rheumatology Providers For Children and Youth (SUPER-KIDZ)
Abstract Number: 2286

Reliability and Smallest Detectable Difference Of The Patient Global Assessment, Pain and Fatigue In Rheumatoid Arthritis Patients
Abstract Number: 2868

Reliability and Validity Of Patient-Reported Joint Counts and Determinants Of Disagreement With The Physician In Recent Onset Rheumatoid Arthritis
Abstract Number: 801

Remaining Pain Is Common In Early RA Patients Treated With Methotrexate – Results From The EIRA Cohort and The Swedish Rheumatology Quality Register
Abstract Number: 1353

Remission After Twelve Month Of Treatment In The Prague Early Rheumatoid Arhritis Cohort
Abstract Number: 1977

Remission At 3 Or 6 Months and Radiographic Non-Progression At 12 Months In Methotrexate-Naïve Rheumatoid Arthritis Patients Treated With Tofacitinib Or Methotrexate: A Post-Hoc Analysis Of The ORAL Start Trial
Abstract Number: 1522

Remission In Spondyloarthritis : ASDAS and Basdai Thresholds From a Prospective Real Life Study
Abstract Number: 446

Remission Rates During Golimumab Treatment For Rheumatoid Arthritis Are Associated With Differences In Baseline Disease States Across Geographic Regions
Abstract Number: 594

Renal Biopsy Findings In Lupus Patient With Insignificant Proteinuria : Relation To Disease Activity and Clinical Manifestations

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].